drugset / Trial / NCT05829434
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Use of magrolimab in combination with standard intensive chemotherapy ("7+3" or CPX-351) in newly diagnosed "ELN 2022 intermediate or adverse-risk" AML or high risk MDS patients, who intend to undergo allogeneic stem cell transplantation
Timeline
- Start
- 2024-03-31
- Primary completion
- 2028-08-30
- Completion
- 2029-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPX-351 | Other / unclassified | — | — |
| Subject | Cytarabine | Small molecule | 100 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 1 g | — |
| Subject | Daunorubicin | Small molecule | 60 mg/m2 | — |
| Subject | Magrolimab | Monoclonal antibody | 30 mg/kg | Intravenous |